Use access key #2 to skip to page content.
$41.91 -0.18 (-0.43%)
11/21/2008 4:00 PM

Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

CAPS Rating:
*****

A global pharmaceutical company, which develops, produces and markets generic drugs covering all major treatment categories.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating TEVA

Add Stock to Watchlist

What the Community Thinks

Total Members

1131 Outperforms
40 Underperforms
 

All-Stars

297 Outperforms
5 Underperforms
 

Wall Street

13 Outperforms
0 Underperforms
 

Members bullish on TEVA are also bullish on:

Members bearish on TEVA are also bearish on:

Ticker Tags

Drugs - Generic (3), Nasdaq 100 (88), Pharmaceuticals (148), Large Cap (279), Israel (23)
Suggest a tag

Teva Pharmaceutical Industries Ltd (ADR) At A Glance

Current Price: $41.91
Last Trade Time: 11/21/2008 4:00 PM
Open: $42.23
Previous Close: $41.91
Daily Range: $39.75 - $42.27
52-Week Range: $35.89 - $50.00
Volume: 11,201,336
Market Cap: $34.27B
P/E Ratio: 13.65
Compare Our Special Broker Offers!

Stock Trends

TEVA VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for TEVA

More Headlines...

Top Bull Pitch

Recs

1

Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Avatar TMFDeej (99.65) Submitted: 9/02/08 1:38 PM

Time to score some cheap drugs, man





Today I have decided to take the plunge and make the first pharma / biotech selection for my CAPS portfolio. Normally I stay far away from these fields because they are not my area of expertise, but I came across a small article in Barron...More

Replies: 2 | Reply | Permalink

Top Bear Pitch

Recs

1

Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Avatar dvd3434 (37.99) Submitted: 7/21/07 5:55 AM

will go down to 38-39$ to check the lows and than will go up again

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 220 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (TEVA)

Avatar ETFinnovators (88.44) Submitted: 11/21/08 10:34 AM : Outperform Start Price: $40.83 TEVA Score: 3.01

Stock Opportunities in a 'Roadhouse Blues' Market

The fear and pessimism behind major selling pressure and stock market losses can be summarized by the late Jim Morrison in a song by The Doors called 'Roadhouse Blues' – "The future's uncertain, and the end is always near." Some stocks that I follow which are trading at less than half of the 20% decline for the S&P 500 ETF (SPY) below its 50-day moving average are highlighted below.

Earlier this week, AspenBio Pharma (APPY) reported that its key clinical trial was nearly 90% enrolled for AppyScore, which is a blood-based diagnostic screening test for appendicitis. APPY expects to reach the required total of 800 patients within weeks, report topline results 4-6 weeks after enrollment is complete, and file a 510(k) with the FDA in early 2009 – which is a quicker approval process for medical devices and tests compared to the PMA process. APPY is currently trading at its 50-day moving average of around 5 bucks, which is impressive given overall market carnage.

Amgen (AMGN) has pulled back below its 50-day moving average of $55.50 at around 52 bucks today since reporting two consecutive quarters in which the Company beat estimates and raised guidance on better sales of its embattled anemia drugs Epogen and Aranesp. The outlook is also improving for Amgen's pipeline, including bone drug denusomab and recently approved Nplate.

Cypress Bioscience (CYPB) is about 8% below its 50-day moving average and has a still pending FDA decision for milnacipran in the treatment of fibromyalgia, which has been widely used as an anti-depressant in Europe and other markets for over a decade. The FDA missed its mid-October decision deadline, but said it expected to resolve the matter in a "matter of weeks", which is encouraging since the agency did not simply delay the deadline by three months as it has done in many recent cases. Another key event is Phase 3 results for the drug for the same indication, with results expected before year-end.

Teva Pharma (TEVA) is trading slightly below its 50-day moving average of around 42 bucks, with a bullish outlook for the Company as the leader in generic drugs which also engages in R&D for brand drugs such as Copaxone. Perrigo (PRGO) is another generic drug company focused more on over-the-counter products, which is trading slightly below its 50-day moving average of 33 bucks.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (TEVA)

Avatar CharlieBombay (21.79) Submitted: 11/20/08 10:24 AM : Underperform Start Price: $41.75 TEVA Score: -5.13

Short-term technical pairs trade with ALXN.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (TEVA)

Avatar LimoPilot1 (59.75) Submitted: 11/17/08 12:09 PM : Outperform Start Price: $43.05 TEVA Score: 10.80

TEVA is an agressive drug producer that searches for drugs that have unenforcable or exempt patent rights. They synthesize generics before they are eligible for production then they are ready to spring when the market allows.


Bold but effective.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (TEVA)

Avatar davidr825 (24.10) Submitted: 11/08/08 11:19 AM : Outperform Start Price: $43.43 TEVA Score: 16.81

With the new adminsitration, generics will get a big boost and this is one of the biggest.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (TEVA)

Avatar craftmacaroni (62.66) Submitted: 11/07/08 12:26 AM : Outperform Start Price: $41.00 TEVA Score: 19.46

This is a secular growth story - a well-managed company with high cash. It specializes in mostly generic drugs. Drugs in some other companies are going off-patent. They are growing their dividends and growing their earnings. In an up market it will underperform. In a down market it will over-perform. But if you look at a long term chart while the dow isn't up much in 10 years, TEVA is - I believe over 700 percent. That's because we've had a couple bubble related recessions. It's a sleep-at-night stock. People will buy their generic meds even in hard times. Also the population is getting older, and people are living longer with more illnesses. I've owned it a long time. I've had occasion to meet people on the board and have known some personally. It's a well-managed company and I have faith in them and their statements. Also the earnings report today was excellent with them raising guidance. It is not cyclical and is especially good in bad times. although it still grows a bit in good times.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 220 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 13 of 13  

picks per page. CHANGE

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackJimCramer 85.65 11/20/08 Outperform 3W $41.91 0%+0.51%-0.51
TrackStanfordRes 48.20 09/25/08 Outperform NS $45.14-7.16%-36.54%+29.39
TrackNeedham < 20 09/25/08 Outperform NS $45.14-7.16%-36.54%+29.39
TrackWachovia < 20 09/22/08 Outperform NS $46.20-9.28%-39.13%+29.85
TrackOppenheimer < 20 09/11/08 Outperform NS $45.55-7.99%-37.90%+29.91
TrackDeutscheSec < 20 07/21/08 Outperform NS $43.24-3.08%-40.02%+36.94
TrackHSBC 92.10 06/30/08 Outperform NS $45.02-6.91%-40.72%+33.81
TrackBofASec 95.85 12/18/07 Outperform NS $43.82-4.36%-48.09%+43.73
TrackBearStearns 25.14 07/09/07 Outperform NS $40.77+2.79%-50.36%+53.15
TrackCreditSuiss < 20 06/06/07 Outperform NS $39.02+7.41%-50.41%+57.82
TrackUBS 85.75 03/23/07 Outperform NS $36.78+13.95%-47.08%+61.04
TrackScottBleier 75.69 12/16/06 Outperform 3M $31.57+32.75%-46.72%+79.47
TrackGaryBSmith 79.82 08/04/06 Outperform 3W $33.70+24.35%-40.85%+65.20

Results 1 - 13 of 13  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links